February 23, 2022 5:02pm

Another free fall with declining sector equities, just when one thought a partial clear signal could have been issued

Pre-open indications: 5 Hits and 7 Miss

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares jumping on “sudden” volume on Wednesday +$0.20 with 3,070 shares traded after 12 p.m. following Tuesday’s 11 a.m. “expeditious” 4,225 shares traded popping the stock +$0.70

Earnings today: Global Blood Therapeutics (GBT)

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -464.85 points (-1.38%); the S&P closed DOWN -79.26 points (-1.84%) while the Nasdaq closed DOWN -344.03 points (-2.57%)

 

Henry’omics:

The three major stock indexes erased earlier gains to trade in negative territory Wednesday morning, with cell and gene therapy stocks swinging into sharply negative territory after advancing at the open.

  • As investors considered the financial market implications of an escalating threat of military attack and greater sanctions on Russia.
  • The mounting geopolitical concerns also further complicate the next move by the Fed, which has so far signaled it is prioritizing bringing down inflationary pressures.

Ongoing geopolitical tensions are contributing to much of the market's volatility.

  • Indexes fell further on Wednesday after the Kyiv government declared a state of emergency and called up reservists.
  • Russian President Putin remains open to a diplomatic solution, but continues to build up his army for an invasion. <IBD>

 

52-week lows:

·         Adverum Biotechnologies (ADVM) all-time low of $1.32

·         uniQure NV (QURE) all-time low of $15.63

·         Sage Therapeutics (SAGE) all-time low of $33.11

·         Fate therapeutics (FATE) all-time low of $31.88

·         Editas Medicine (EDIT) all-time low of $14.65

·         Solid BioSciences (SLDB) all-time low of $0.89

·         Cellectis SA (CLLS) all-time low of $4.58

·         Verastem (VSTM) all-time low of $1.19

·         bluebird bio (BLUE) all-time low of $5.95

·         CRISPR Therapeutics (CRSP) all-time low of $54.60

 

RegMed Investors’ (RMi) pre-open: overcoming resistance to instill a little lost confidence. It ain’t over until the bottoms bounce” … https://www.regmedinvestors.com/articles/12312

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

·         Wednesday opened positive at 17 up/16 downs, 1 flat and 1 acquired, strayed negative at the mid-day at 10/24 1 acquired, ending with a negative close of 8/26 and 1 acquired;

·         Tuesday opened negative at 3 up/29 downs, 2 flats and 1 acquired, stayed negative at the mid-day at 9/22, 3 flats and 1 acquired, ending with a negative close of 7/25, 2 flats and 1 acquired;

 

Pre-open Indications: 5 Hits <AxoGen (AXGN +$0.72), Fate Therapeutics (FATE -$1.31), Global Blood Therapeutics (GBT -$2.44), Sage Therapeutics (SAGE -$1.43)> 7 Miss < CRISPR Therapeutics (CRSP -$2.41), Editas Medicine (EDIT -$0.60), Intellia Therapeutics (NTLA -$4.14), Vericel (VCEL -$1.10), bluebird bio (BLUE -$0.32), Regenxbio (RGNX -$0.40), uniQure NV (QURE -$0.31)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … added Global Blood Therapeutics (GBT)

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares jumping on “sudden” volume on Wednesday +$0.20 with 3,070 shares traded after 12 p.m. following Tuesday’s 11 a.m. of 4,225 shares traded popping the stock +$0.70

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 3 of the 8-upside having higher than the 3-month average volume with LOW volume of 6 of 26-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday   the IBB closed down -2.14% and XBI closed down -4.04%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +2.12 points or +7.36% at 30.93

 

 

Jumping with share pricing momentum (8 of 8):

·         ReNeuron (RENE.L +$1.50 after Tuesday’s -$1.50),

·         AxoGen (AXGN +$0.72),

·         Alnylam Pharmaceuticals (ALNY +$0.66 after Tuesday’s -$0.69),

·         Biostage (BSTG +$0.20 after Tuesday’s +$0.62),

·         Homology Medicine (FIXX +$0.19 after Tuesday’s -$1.26),

·         Voyager Therapeutics (VYGR +$0.08 after Tuesday’s +$0.09),

·         Pluristem (PSTI +$0.07),

·         Bellicum Pharmaceuticals (BLCM +$0.02),

Hammered in today’s market (10 of 26):

·         Intellia Therapeutics (NTLA -$4.14 after Tuesday’s -$2.33),

·         Global Blood Therapeutics (GBT -$2.44 after Tuesday’s -$1.30),

·         CRISPR Therapeutics (CRSP -$2.41 after Tuesday’s -$2.63),

·         Ultragenyx (RARE -$2.13 after Tuesday’s +$0.21),

·         Sage Therapeutics (SAGE -$1.43),

·         Fate therapeutics (FATE -$1.31),

·         Vericel (VCEL -$1.10 after Tuesday’s -$1.62),

·         BioLife Solutions (BLFS -$0.80 after Tuesday’s -$0.34),

·         Ionis Pharmaceuticals (IONS -$0.93),

·         Editas Medicine (EDIT -$0.61 after Tuesday’s -$0.19),

Closing Flat:

·         1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Wednesday closed negative with 8 incliner, 26 decliners and 1 acquired
  • Tuesday closed negative with 7 incliners, 25 decliners, 2 flats and 1 acquired
  • Monday (2/21) was a holiday, President’s Day 

 

The BOTTOM LINE: The only easy day, was not yesterday, nor last Friday, Thursday, Wednesday or even the previous Monday, Friday or Thursday – when was it – Tuesday (2/15), Wednesday (2/9), Monday (2/7) …

Cell and gene therapy sector stocks was locked again in the penalty boy over market pressures and lack of any confidence over geo-political “issues” and enhanced by an FDA clinical hold on FIX – risk, risk and more risk as we run into earnings season’s busiest week.

We are just going with the flow as we trip and fall to the weekend …

Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.

Earnings’ reporting:

·         Sage Therapeutics (SAGE), Thursday, 2/24

·         Ionis Pharmaceuticals (IONS) - Thursday, 2/24

·         Sangamo Therapeutics (SGMO) - Thursday, 2/24

·         Editas Medicine (EDIT) - Thursday, 2/24

·         Fate therapeutics, Monday, 2/28

·         Regenxbio (RGNX), Tuesday, 2/1

·         Athersys (ATHX), Tuesday, 3/15

 

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.